Endocrine abnormities and vessels in patients with diabetes

Czech version

Authors: J. Čáp
Authors‘ workplace: přednosta prof. MU Dr. Jaroslav Malý, CSc. ; II. interní klinika Lékařské fakulty UK a FN Hradec Králové
Published in: Vnitř Lék 2010; 56(4): 280-283
Category: 11th National Diabetes Symposium "Diabetes and Angiology", Hradec Kralove, 5 to 6 June 2009

Overview

Endocrine impairment is more common in patients with diabetes than in general population. Both hyper‑ and hypothyroidism increases cardiovascular morbidity and mortality. Subclinical hypothyroidism is a risk factor for coronary hearth disease in patients younger than 65 years. In elderly is its influence questionable or even preventive and the benefit of substitution should be weighted against the risks. Treatment with glucocorticoids in a dose of 7.5 mg methylprednisolone and higher considerably increases risk of vascular impairment. Patients cured from endogenous Cushing’s syndrome maintain increased cardiovascular risk factors and structural changes of vessels. Subclinical hypercortisolism seems to have little effect. Growth hormone (GH) insufficiency increases cardiovascular risks and contributes to increased mortality of these patients. To the contrary increased GH production in acromegaly effect more heart than vessels. Hypogonadism is established risk factor for ischemic accidents in men. The relationship between hypogonadism and diabetes is bidirectional. Low testosterone level increases the risk of type‑ 2 diabetes and in diabetics is the testosterone level often low. Substitution with testosterone can not only ameliorate hypogonadal symptoms but also decrease cardiovascular risk and even improve control of diabetes.

Key words:
diabetes mellitus – atherosclerosis – hypothyroidism – hypercortisolism – growth hormone – testosterone

Sources

1. Neves C, Alves M, Medina JL et al. Thyroid diseases, dyslipidemia and cardiovascular pathology. Rev Port Cardiol 2008; 27: 1211– 1236.

2. Singh S, Duggal J, Molnar J et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all‑cause mortality: a meta‑analysis. Int J Cardiol 2008; 125: 41– 48.

3. Haentjens P, Van Meerhaeghe A, Poppe Ket al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all‑cause mortality based on time‑ to‑ event data from cohort studies. Eur J Endocrinol 2008; 159: 329– 341.

4. Parle JV, Maisonneuve P, Sheppard MC et al. Prediction of all‑cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10‑year cohort study. Lancet 2001; 358: 861– 865.

5. Jiskra J, Límanová Z, Antošová M. Tyreopatie, dyslipidemie a kardiovaskulární rizika. Vnitř Lék 2007; 53: 382– 385.

6. Razvi S, Ingoe L, Keeka G et al. The beneficial effect of L‑ thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 1715– 1723.

7. Biondi B, Galderisi M, Pagano L et al. Endothelial‑ mediated coronary flow reserve in patients with mild thyroid hormone deficiency. Eur J Endocrinol 2009; 161: 323– 329.

8. Rodondi N, Aujesky D, Vittinghoff E et al. Subclinical hypothyroidism and the risk of coronary heart disease: a meta‑analysis. Am J Med 2006; 119: 541– 551.

9. Ochs N, Auer R, Bauer DC et al. Meta‑analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148: 832– 845.

10. Razvi S, Shakoor A, Vanderpump M et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab 2008; 93: 2998– 3007.

11. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007; 157: 545– 559.

12. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764– 770.

13. Marek J, Hána V, Kršek M. Jak ovlivňujíi kortikoidy, růstový hormon a estrogeny lipidy a aterosklerózu. Vnitř Lék 2007; 53: 386– 390.

14. Anagnostis P, Athyros VG, Tziomalos Ket al. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009; 94: 2692– 2701.

15. Colao A, Pivonello R, Spiezia S et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664– 2672.

16. Sereg M, Szappanos A, Toke J et al. Atherosclerotic risk factors and complications in patients with non‑functioning adrenal adenomas treated with or without adrenalectomy: a long‑term follow‑up study. Eur J Endocrinol 2009; 160: 647– 655.

17. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285– 288.

18. Maison P, Griffin S, Nicoue‑ Beglah M et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH‑ deficient adults: a Metaanalysis of Blinded, Randomized, Placebo‑ Controlled Trials. J Clin Endocrinol Metab 2004; 89: 2192– 2199.

19. Colao A, Di Somma C, Spiezia S et al. Growth hormone treatment on atherosclerosis: results of a 5‑year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2008; 93: 3416– 3424.

20. Čáp J. Substituce růstového hormonu u dospělých: zlepšení kvality, nebo prodloužení života? Vnitř Lék 2003; 49: 589– 591.

21. Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425– 431.

22. Holdaway IM, Bolland MJ, Gamble GD. A meta‑analysis of the effect of lowering serum levels of GH and IGF‑I on mortality in acromegaly. Eur J Endocrinol 2008; 159: 89– 95.

23. Bogazzi F, Battolla L, Spinelli C et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five‑year prospective study. J Clin Endocrinol Metab 2007; 92: 4271– 4277.

24. Mulligan T, Frick MF, Zuraw QC et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762– 769.

25. Ding EL, Song Y, Malik VS et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta‑analysis. JAMA 2006; 295: 1288– 1299.

26. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448– 4456.

27. Alibhai SM, Duong‑Hua M, Sutradhar Ret al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452– 3458.

28. Traish AM, Saad F, Feeley RJ et al. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477– 494.

29. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30: 23– 32.

30. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1– 7.

31. Kapoor D, Goodwin E, Channer KS et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899– 906.